Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2779-2788

  Serizawa, Masakuni ^a   Kusuhara, Masatoshi ^a   Zangiacomi, Vincent ^a   Urakami, Kenichi ^a   Watanabe, Masaru ^a   Takahashi, Toshiaki ^a   Yamaguchi, Ken ^a   Yamamoto, Nobuyuki ^a,b   Koh, Yasuhiro ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Copy number alteration; EGFR TKI resistance; Glutamine metabolism; Metabolomics; MYC; Non small cell lung cancer

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; CITRULLINE; ERLOTINIB; FRUCTOSE 1,6 BIS PHOSPHATE; FRUCTOSE 6 PHOSPHATE; GAMMA GLUTAMYLTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE 1; GAMMA GLUTAMYLTRANSFERASE 5; GLUCOSE 6 PHOSPHATE; GLUTAMINE; GLUTATHIONE TRANSFERASE T1; GLUTATHIONE TRANSFERASE T2; MYC PROTEIN; ONCOPROTEIN; ORNITHININE; TRANSFERASE; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CAPILLARY ELECTROPHORESIS; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DISEASE MARKER; GENE AMPLIFICATION; GENOMICS; GLUTATHIONE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLOMICS; NON SMALL CELL LUNG CANCER; TIME OF FLIGHT MASS SPECTROMETRY; ADENOCARCINOMA; COPY-NUMBER ALTERATION; DRUG EFFECT; DRUG RESISTANCE; EGFR-TKI RESISTANCE; GENETICS; GLUTAMINE METABOLISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; METABOLOME; MYC; NON-SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

COPY-NUMBER ALTERATION; EGFR-TKI RESISTANCE; GLUTAMINE METABOLISM; METABOLOMICS; MYC; NON-SMALL CELL LUNG CANCER;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, CAPILLARY; HUMANS; LUNG NEOPLASMS; METABOLOME; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84906306531     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E and Ladanyi M: Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8: 823-859, 2013.
2. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
3. Ohashi K, Maruvka YE, Michor F and Pao W: Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31: 1070-1080, 2013.
4. Casado-Vela J, Cebrian A, Gomez del Pulgar MT and Lacal JC: Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol 13: 617-628, 2011.
5. Deyati A, Younesi E, Hofmann-Apitius M and Novac N: Challenges and opportunities for oncology biomarker discovery. Drug Discov Today 18: 614-624, 2013.
6. Beger R: A Review of Applications of Metabolomics in Cancer. Metabolites 3: 552-574, 2013.
7. Spratlin JL, Serkova NJ and Eckhardt SG: Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15: 431-440, 2009.
8. Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532, 2013.
9. Backshall A, Sharma R, Clarke SJ and Keun HC: Pharmaco-metabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res 17: 3019-3028, 2011.
10. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG and Serkova NJ: Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res 15: 3442-3450, 2009.
11. Serizawa M, Takahashi T, Yamamoto N and Koh Y: Combined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 8: 259-269, 2013.
12. Serizawa M, Takahashi T, Yamamoto N and Koh Y: Genomic Aberrations Associated with Erlotinib Resistance in Non-small Cell Lung Cancer Cells. Anticancer Res 33: 5223-5233, 2013.
13. Ramautar R, Somsen GW and de Jong GJ: CE-MS for metabolomics: developments and applications in the period 2010-2012. Electrophoresis 34: 86-98, 2013.
14. Urakami K, Zangiacomi V, Yamaguchi K and Kusuhara M: Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line. Biomed Res 34: 221-229, 2013.
15. Fujimura Y, Kurihara K, Ida M, Kosaka R, Miura D, Wariishi H, Maeda-Yamamoto M, Nesumi A, Saito T, Kanda T, Yamada K and Tachibana H: Metabolomics-driven nutraceutical evaluation of diverse green tea cultivars. PLoS One 6: e23426, 2011.
16. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB and Thompson CB: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787, 2008.
17. Yuneva M, Zamboni N, Oefner P, Sachidanandam R and Lazebnik Y: Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178: 93-105, 2007.
18. Dang CV, Le A and Gao P: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483, 2009.
19. Wise DR and Thompson CB: Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433, 2010.
20. Townsend DM and Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375, 2003.
21. Corti A, Franzini M, Paolicchi A and Pompella A: Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer research 30: 1169-1181, 2010.
22. Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ and Cho BC: Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Ther 12: 2145-2156, 2013.
23. Galluzzi L, Kepp O, Heiden MG and Kroemer G: Metabolic targets for cancer therapy. Nat Rev Drug Discov 12: 829-846, 2013.
24. Vander Heiden MG: Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684, 2011.
25. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E and Hall MN: Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 47: 349-358, 2012.
26. Cavill R, Kamburov A, Ellis JK, Athersuch TJ, Blagrove MS, Herwig R, Ebbels TM and Keun HC: Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol 7: e1001113, 2011.